(Q44216175)

30 November 2017

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats (English)

1 reference

30 November 2017

0 references

Stefan Carlsson

1

1 reference

PubMed ID

12431484

30 November 2017

Margareta Elg

series ordinal

2

1 reference

PubMed ID

12431484

30 November 2017

Christer Mattsson

series ordinal

3

1 reference

30 November 2017

1 August 2002

1 reference

30 November 2017

1 reference

30 November 2017

107

1 reference

30 November 2017

3-4

1 reference

30 November 2017

163-168

1 reference

Prevention of venous thromboembolism

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

1 reference

7 January 2021

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Kinetics of the inhibition of thrombin by hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

10.1016/S0049-3848(02)00257-8

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12431484